title: Does paclitaxel-carboplatin chemotherapy in a dose-dense regimen enhance survival of BRCA-related ovarian cancer patients?
abstract: In a group of 6 BRCA-related ovarian cancer patients presenting with clinical relapse, paclitaxel-carboplatin (TC) in a dose-dense regimen was administered to evaluate the response and tolerability compared with those of the sporadic group and of the patients using a regimen administered every 3 weeks. All patients were carboplatin sensitive at the time of first relapse: 4 patients showed intermediate sensitivity (6-12 months), and 2 patients were truly carboplatin sensitive (>12 months) at first relapse and first administration of a TC dose-dense regimen. A total of 14 dose-dense regimens were administered in a median 5th line (range, 2nd-10th line). A median of 2 dose-dense regimens (range, 1-4) was given per patient. After first administration of the TC dose-dense regimen (median, 3rd line), this resulted in response in all patients: complete remission in 33% and partial remission in the remaining 67%. Furthermore, after another consecutive line of TC dose-dense regimen, 100% response (75% with partial remission and 25% with complete remission) was reached. The results are encouraging and support the observation of extreme carboplatin sensitivity of BRCA-related ovarian cancer. The use of a TC dose-dense regimen might be even more effective.
authors: Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University Hospitals Leuven, Leuven, Belgium. karin.leunen@uz.kuleuven.ac.be
authors: Karin
authors: K
authors: Leunen
authors: Isabelle
authors: I
authors: Cadron
authors: Toon
authors: T
authors: Van Gorp
authors: Frédéric
authors: F
authors: Amant
authors: Patrick
authors: P
authors: Berteloot
authors: Patrick
authors: P
authors: Neven
authors: Eric
authors: E
authors: Legius
authors: Ignace
authors: I
authors: Vergote
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage* / Q000009:adverse effects; D019313:BRCA1 Protein / Q000235:genetics*; D016190:Carboplatin / Q000008:administration & dosage* / Q000009:adverse effects; D002277:Carcinoma / Q000188:drug therapy* / Q000235:genetics / Q000401:mortality; D002471:Cell Transformation, Neoplastic / Q000235:genetics; D004305:Dose-Response Relationship, Drug; D005260:Female; D020022:Genetic Predisposition to Disease; D006801:Humans; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000401:mortality; D017239:Paclitaxel / Q000008:administration & dosage* / Q000009:adverse effects; D012189:Retrospective Studies; D016019:Survival Analysis; D016896:Treatment Outcome
chemical_list: D019313:BRCA1 Protein; C492913:BRCA1 protein, human; D016190:Carboplatin; D017239:Paclitaxel